Orazio Fortunato
Overview
Explore the profile of Orazio Fortunato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
952
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghidotti P, Petraroia I, Fortunato O, Pontis F
Extracell Vesicles Circ Nucl Acids
. 2024 Dec;
4(1):59-71.
PMID: 39698297
Lung cancer is the deadliest cancer worldwide, primarily because of its metastatic spread. Extracellular vesicles (EVs) are small lipid-bilayer particles released by almost all types of cells. EVs play fundamental...
2.
Bertolini G, Fortunato O, Lucotti S
Front Immunol
. 2024 Nov;
15:1504676.
PMID: 39483460
No abstract available.
3.
Maiullari F, Milan M, Chirivi M, Ceraolo M, Bousselmi S, Fratini N, et al.
Biofabrication
. 2024 Jul;
16(4).
PMID: 38986455
Over the past three decades, cell therapy development has fallen short of expectations, with many cellular sources demonstrating a 'Janus effect' and raising safety concerns. Extracellular vesicles (EVs), supported by...
4.
Petraroia I, Ghidotti P, Bertolini G, Pontis F, Roz L, Balsamo M, et al.
Cell Death Dis
. 2023 Oct;
14(10):681.
PMID: 37838700
Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer development. COPD induces activation of hypoxia-induced signaling, causing remodeling of surrounding microenvironmental cells also modulating the release and...
5.
Pontis F, Roz L, Fortunato O, Bertolini G
Front Oncol
. 2023 May;
13:1116783.
PMID: 37207158
Lung cancer is the deadliest cancer in the world, with the majority of patients presenting with advanced or metastatic disease at first diagnosis. The lungs are also one of the...
6.
Casanova M, Pontis F, Ghidotti P, Petraroia I, Venturini L, Bergamaschi L, et al.
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430468
Adolescents and young adults (AYA) with rhabdomyosarcoma (RMS) form a subgroup of patients whose optimal clinical management and best possible access to care remain a challenge and whose survival rates...
7.
Signorelli D, Ghidotti P, Proto C, Brambilla M, De Toma A, Ferrara R, et al.
Front Immunol
. 2022 Oct;
13:987639.
PMID: 36203609
PD-L1 in tumor cells is the only used biomarker for anti PD1/PD-L1 immune-checkpoints inhibitors (ICI) in Non Small Cell Lung Cancer (NSCLC) patients. However, this parameter is inaccurate to predict...
8.
Panunzi A, Madotto F, Sangalli E, Riccio F, Sganzaroli A, Galenda P, et al.
Cardiovasc Diabetol
. 2022 Sep;
21(1):196.
PMID: 36171587
Background: Cell therapy with autologous peripheral blood mononuclear cells (PB-MNCs) may help restore limb perfusion in patients with diabetes mellitus and critical limb-threatening ischemia (CLTI) deemed not eligible for revascularization...
9.
Fortunato O, Huber V, Segale M, Cova A, Vallacchi V, Squarcina P, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Sep;
31(11):2020-2029.
PMID: 36112827
Background: Low-dose CT (LDCT) screening trials have shown that lung cancer early detection saves lives. However, a better stratification of the screening population is still needed. In this respect, we...
10.
Bordin A, Chirivi M, Pagano F, Milan M, Iuliano M, Scaccia E, et al.
Cell Prolif
. 2022 Aug;
55(11):e13312.
PMID: 35946052
Objectives: Extracellular vesicles (EVs) are key biological mediators of several physiological functions within the cell microenvironment. Platelets are the most abundant source of EVs in the blood. Similarly, platelet lysate...